All In Biotech

Drug Trial Radar · NCT05810103

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

A Multi-center, Single-arm, Phase І Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

12

Planned (sponsor's estimate)

Start

Apr 6, 2023

Primary completion

Dec 23, 2023

Study completion Mar 23, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of DP303c in patients with HER2-positive advanced solid tumors.

Conditions

  • HER2-positive Advanced Solid Tumors

Interventions

  • DP303cDrug

    DP303c injection, 3.0 mg/kg, every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration [Cmax]Time frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)
  2. Area Under Curve from 0 to the last point (AUC0-last)Time frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)
  3. Area Under Curve from t 0 to the infinity (AUC0-inf)Time frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)
  4. Time to Reach Peak Serum Concentration (Tmax)Time frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.